drugset / Trial / NCT05866510
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
Phase 2
Unknown
47 enrolled
Peking University
Beijing Biostar Pharmaceuticals Co., Ltd. · collabChia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | Intravenous |
| Background | Cimetidine | Small molecule | 300 mg | Intravenous |
| Background | Dexamethasone | Small molecule | 10 mg | Intravenous |
| Background | Diphenhydramine | Unknown | 40 mg | Intramuscular |